Could a wearable sensor replace fingerstick checks for sepsis patients in the ICU?

NCT ID NCT07686939

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether a continuous glucose monitor (CGM) — a small sensor worn on the arm — can help manage blood sugar levels more effectively than standard fingerstick checks in critically ill sepsis patients. Sepsis patients often have unstable blood sugar, which can lead to complications. The study compares the CGM's accuracy, how well it helps staff follow treatment guidelines, and whether it saves time. If it works, CGM could offer a more reliable and less labor-intensive way to monitor glucose in the ICU.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FreeStyle Libre II continuous glucose monitor (device)
What this could lead to
If successful, CGM could become a standard tool in ICUs for managing blood sugar in sepsis patients, potentially reducing complications and nursing workload.
What could go wrong
This is a small, early-stage trial (60 patients) focused on accuracy and feasibility, not long-term outcomes. CGM may not prove reliable enough or improve patient survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLYCEMIC CONTROL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Taizhou Municipal Hospital

    Taizhou, Zhejiang, 318000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.